The Strength and Importance of Government-Funded Patents for Approved Drugs (Reply)

Gabriele SME, Martin MJ, Kesselheim AS, Tu SS - Nature Biotechnology

  • Innovation Incentives and Competition

Summary:

In response to a letter about their original analysis, the authors clarify that the Bayh–Dole Act does allow the government to exercise march-in rights when patented, government-funded drugs are not made available on reasonable terms, including cases of excessive pricing. TApplying these rights aligns with Congress’s original intent to ensure publicly funded medicines serve the public interest.

VIEW SOURCE

Recent Work from PORTAL

Talk bubble graphics representing commentary and opinion.

The Impact of Semantics in Medicines Regulation

Costa E, Kesselheim AS - Journal of Law, Medicine, & Ethics

  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Delisted Patents on Pharmaceuticals, 1998-2024

Kirby-Rivera L, Feldman WB, Kim M, Kosmopoulou G, Kesselheim AS, Tu SS - Journal of Law, Medicine, & Ethics

  • Innovation Incentives and Competition
Talk bubble graphics representing commentary and opinion.

Delays in Access to Generic Semaglutide Point to Key Missing Pieces in Canada’s Drug Approval System

Eisenkraft Klein D, Kesselheim AS - Health Policy

  • Innovation Incentives and Competition
  • Regulation and Clinical Evidence
Canada approved its first generic semaglutide nearly four months after market exclusivity expired, with delays arising from the absence of clear standards for demonstrating equivalence between fully synthetic generics and the brand-name product. Regulators should publish equivalence standards so manufacturers can build the required evidence into their initial submissions, helping lower-cost alternatives reach patients sooner.
View Source